Benchmark Holdings (BMK)

 

BMK Share PerformanceMore

52 week high111.50 30/01/17
52 week low35.00 09/10/17
52 week change -26.50 (-32.32%)
4 week volume15,272,173 20/11/17

Media for (BMK)

Presenter: Presenter
26/06/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Broker Forecast - Numis issues a broker note on Benchmark Holdings Plc

Numis today upgrades its investment rating on Benchmark Holdings Plc (LON:BMK) to buy (from add) and set its price t...

Benchmark sees 100% success in sea lice treatment trial

Benchmark, the aquaculture health, nutrition, and genetics business, has announced the results of its highly successful firs...

Commercial scale field trial of sea lice treatment

RNS Number: 0253Z Benchmark Holdings PLC 12 December 2017 RNS Benchmark Holdings plc ("Benchmark" or the "Company") Benchmark announces the success of its next generation sea lice treatment Ectosan during its first commercial scale field trials Breakthrough development in addressing one of the salmon industry's biggest disease challenges Benchmar...

Benchmark participates in gene editing research

RNS Number: 6250Y Benchmark Holdings PLC 07 December 2017 RNS Reach Benchmark Holdings plc ("Benchmark" or the "Company") Benchmark participates in gene editing research to develop disease resistance in salmon Benchmark, the aquaculture health, nutrition, and genetics business, is pleased to announce its participation in an important gene editing re...

Benchmark adjusted earnings ahead of forecasts

Benchmark Holdings expects adjusted EBITDA for the 12 months to the end of September to be ahead of previous forecas...

Trading Update and Notice of Results

RNS Number: 3602Y Benchmark Holdings PLC 05 December 2017 5 December 2017 Information within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014. Benchmark Holdings plc ("Benchmark", the "Company" or the "Group") Trading Update and Notice of Results Benchmark, ...

Benchmark develops disease-resistant shrimp

Benchmark, the aquaculture health, nutrition and breeding and genetics business, has developed specific pathogen resistant...

Development of disease-resistant shrimp

RNS Number: 8495V Benchmark Holdings PLC 08 November 2017 Benchmark Holdings plc ("Benchmark", the "Company" or the "Group") Development of disease-resistant shrimp for the Asian market Benchmark, the aquaculture health, nutrition and breeding and genetics business, is pleased to announce that it has developed specific pathogen resistant ("SPR") s...

Fundamental DataMore

EPS-4.39
Dividend yield0 %

Latest discussion posts More

  • Gene editing research

    Benchmark Holdings plc ("Benchmark" or the "Company") Benchmark participates in gene editing research to develop disease resistance in salmon Benchmark, the aquaculture ...
    7-Dec-2017
    IOMINVESTCOM
  • Trading Update and Notice of Results

    5 December 2017 Information within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulations (EU) No. ...
    5-Dec-2017
    IOMINVESTCOM
  • Other news

    Positive news on BMKs website. All good Information to indicate future ...
    1-Dec-2017
    estiente

Users' HoldingsMore

Users who hold Benchmark Holdings also hold..

Codes & Symbols

ISINGB00BGHPT808
SymbolsBMK, LSE:BMK, BMK.L, BMK:LN, LON:BMK, XLON:BMK

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account